Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126540192 | 12654019 | 2 | F | 201302 | 20160819 | 20160816 | 20160901 | EXP | TR-MLMSERVICE-20160729-0371363-1 | TR-ACCORD-043110 | ACCORD | ALAGOZ E, INCE S, OKUYUCU K, AYAN A, SAN H, KARADURMUS N ET AL. COMPLETE REMISSION ON 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY AFTER NIVOLUMAB TREATMENT IN A PATIENT WITH INDOLENT HODGKIN LYMPHOMA.TRANSLATIONAL CANCER RESEARCH. 2016; 5(3):320-323. | 24.00 | YR | M | Y | 0.00000 | 20160901 | OT | TR | TR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126540192 | 12654019 | 1 | PS | ETOPOSIDE. | ETOPOSIDE | 1 | 74513 | ||||||||||||
| 126540192 | 12654019 | 2 | SS | CARMUSTINE | CARMUSTINE | 1 | HIGH DOSE BCNU | 0 | |||||||||||
| 126540192 | 12654019 | 3 | SS | CYTARABINE/CYTARABINE HYDROCHLORIDE/CYTARABINE OCFOSFATE | CYTARABINE | 1 | 0 | ||||||||||||
| 126540192 | 12654019 | 4 | SS | MELPHALAN | MELPHALAN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126540192 | 12654019 | 1 | Hodgkin's disease |
| 126540192 | 12654019 | 2 | Hodgkin's disease |
| 126540192 | 12654019 | 3 | Hodgkin's disease |
| 126540192 | 12654019 | 4 | Hodgkin's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126540192 | 12654019 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126540192 | 12654019 | Drug ineffective | |
| 126540192 | 12654019 | Hodgkin's disease nodular sclerosis | |
| 126540192 | 12654019 | Malignant neoplasm progression | |
| 126540192 | 12654019 | Stem cell transplant | |
| 126540192 | 12654019 | Therapy non-responder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |